Canada records second case of rare blood clot after AstraZeneca shot

TORONTO, CANADA (AFP) – Canadian health authorities said on Saturday the country has recorded a second case of rare but serious blood clotting linked to AstraZeneca’s Covid-19 vaccine, but still recommend the shot for use.

The patient, who lives in the western province of Alberta and received a version of the AstraZeneca vaccine supplied by the Serum Institute of India, “has received treatment and is recovering”, Canadian health authorities wrote on Twitter.

Canada reported its first case of blood clotting associated with low platelets on Tuesday in a Quebec woman who received the same shot.

Blood clot formations linked to the AstraZeneca vaccine “remain very rare” and Canada still believes that the vaccine’s benefits “outweigh the potential risks”, Health Canada and the Public Health Agency of Canada said.

Canada’s health authorities added that they would “continue to monitor the use of all #COVID19 vaccines closely and examine and assess any new safety concerns”.

At the end of March, Canada’s National Advisory Committee on Immunization (NACI) recommended suspending the use of the AstraZeneca vaccine in people under the age of 55 while it evaluated the risks.

However Health Canada said on Wednesday that according to its analysis, limiting the use of the vaccine to certain populations was not necessary for the moment.

Vials of the AstraZeneca and Moderna COVID-19 vaccines are pictured at the pharmacy of the Sant’Andrea hospital in Vercelli, Piedmont. PHOTO: AFP